107 related articles for article (PubMed ID: 24831132)
1. Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholder.
Smith MR
Biol Blood Marrow Transplant; 2014 Jul; 20(7):905-6. PubMed ID: 24831132
[No Abstract] [Full Text] [Related]
2. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
Ramsdale E; Van Besien K
Leuk Lymphoma; 2011 Aug; 52(8):1415-7. PubMed ID: 21599586
[No Abstract] [Full Text] [Related]
3. Allogeneic stem cell transplantation for patients with resistant high-grade lymphoma: what is the potential of reduced-intensity conditioning?
Dreger P
Ann Oncol; 2002 Sep; 13(9):1507. PubMed ID: 12196382
[No Abstract] [Full Text] [Related]
4. Transplantation for lymphoma: good for the brain as well as the body?
Bierman PJ; Armitage JO
Biol Blood Marrow Transplant; 2012 Jan; 18(1):1-2. PubMed ID: 22079472
[No Abstract] [Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation following a cytoreductive autograft in patients with non-Hodgkin's lymphoma who relapse after autologous transplantation.
Yang DH; Lee JJ; Kim YK; Cho SH; Chung IJ; Kim HJ
Bone Marrow Transplant; 2004 Nov; 34(10):915-6. PubMed ID: 15517010
[No Abstract] [Full Text] [Related]
7. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
Gopal AK; Pagel JM; Rajendran JG; Maloney DG; Appelbaum FR; Sorror ML; Sandmaier BM; Storb R; Press OW
Biol Blood Marrow Transplant; 2006 Jul; 12(7):697-702. PubMed ID: 16785058
[TBL] [Abstract][Full Text] [Related]
8. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma.
Morris EC; Mackinnon S
Best Pract Res Clin Haematol; 2005 Mar; 18(1):129-42. PubMed ID: 15694189
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
10. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma.
Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Holmberg LA; Stewart FM
Oncology (Williston Park); 2003 May; 17(5):627-32, 635, 640; discussion 640-2. PubMed ID: 12800792
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of combining ATRA with G-CSF in HSPC mobilization; a pilot study in multiple myeloma and non-Hodgkin's lymphoma patients.
Herbert KE; True S; McArthur G; Prince HM
Bone Marrow Transplant; 2007 Oct; 40(8):801-3. PubMed ID: 17680017
[No Abstract] [Full Text] [Related]
15. A clinical trial combining megakaryocytes and haematopoietic stem cells to promote engraftment after autologous transplantation.
Trebeden-Negre H; Choquet S; Tanguy ML; Rozenzwajg M; Azar N; Lefrère F; Heshmati F; Belhocine R; Vieillard V; Norol F
Br J Haematol; 2018 Oct; 183(1):139-142. PubMed ID: 28891211
[No Abstract] [Full Text] [Related]
16. Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma?
Ho AY; Pagliuca A
Hematology; 2002 Dec; 7(6):345-54. PubMed ID: 12475739
[TBL] [Abstract][Full Text] [Related]
17. Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma.
Bierman PJ; Phillips GL
Cancer Treat Res; 2009; 144():357-97. PubMed ID: 19779882
[No Abstract] [Full Text] [Related]
18. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
19. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Bone Marrow Transplant; 2008 Feb; 41(4):355-61. PubMed ID: 18026153
[TBL] [Abstract][Full Text] [Related]
20. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
